FibroScan®
Currently, there are no FDA-approved NASH drug treatments; 4 drugs in phase III trials are among approximately 55 in research and development. Experts state that the global market for NASH could exceed $35 billion. Given the shift to value-based medicine and the significant cost implications of NASH, the study explored which outcomes and quality measures KOLs would recommend for value-based contracting.
The KOLs involved in this study have been integral advisors on a real-world evidence initiative launched in 2018 by The Kinetix Group, in partnership with NASH Network (NASHNET). The collaboration is focused on improving NASH care delivery through a pilot with leading academic medical centers using Echosens’ FibroScan® system device as part of a standard workup to appropriately identify patients with progressive nonalcoholic fatty liver disease (NAFLD). FibroScan® is a non-invasive technology that quickly provides a quantitative assessment of liver stiffness and fat at the point of care.
The Kinetix Group and NASHNET are committed to pioneering and defining the best practice model for NASH care delivery. This study demonstrates the need for an appropriate NASH care model that is standardized and evidence-based in the evolution towards value-based care.
NASH Network (NASHNet): Nonalcoholic Steatohepatitis (NASH) is a challenging high-volume chronic condition that lacks a standardized care delivery model. Our multidisciplinary teams of experts are here to change that. NASHNET is a global Centers of Excellence Network represented by leading healthcare systems committed to NASH care delivery innovation. Our charter members are collaborating to solve for key challenges across the NASH spectrum, including care coordination, population health, real-world evidence, and clinical trials. To learn more, go to www.nashnetwork.org.
The Kinetix Group (TKG) empowers life science companies to effectively engage with health system and payer customers by developing strategies and real-world solutions aimed at impacting the right patient, at the right time, with the right care. TKG also works directly with health systems and payers to build and implement value-based delivery models for identified patient populations. To learn more, go to www.thekinetixgroup.com.
